About Anygen
Anygen is a publicly listed company based in Gwangju (South Korea) founded in 2000, and was acquired by HLB in March 2025. Peptide API and drug developer for cancer pain disorders. The company has 83 employees. Its chief executive, as recorded, is Jae Kim. Its focus areas include Diversified Pharmaceuticals.
Company details
Founded in 2000 and based in Gwangju, South Korea, operations center on the biotech sector with GMP and non-GMP production of custom, generic, and catalog peptides. Services are delivered via the Nano-Bio Research center. Three drug candidates are under development in the GIST unit: an anti-cancer agent targeting head and neck cancers, a peptide-based treatment for neuropathic pain, and an oral delivery platform. Licensing is anticipated after preclinical trials.
- Headquarters Gwangju, South Korea
- Employees 83
- Stage Acquired
- SectorsHealthcare
- Website anygen.com
- Acquired by HLB (Mar 2025)
- Legal Name Hlb Pep Co. Ltd.
Funding Insights of Anygen
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of Anygen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2014 | Unspecified | β | β |
2 investors in total: 2 institutional.
Investors in Anygen
Anygen has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include HLB and Solidus Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| solidusvc.com | ||||
Marine composite materials are manufactured for industry applications. | 1985 | hlbkorea.com | Ulsan, South Korea |
Investor details for Anygen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Anygen
1 people are tracked at Anygen (1 in leadership); the tracked headcount is 83.
| Name | Role | Group |
|---|---|---|
Jae Kim | CEO | Leadership |
Complete people profiles for Anygen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Anygen
Anygen is a publicly listed company on the KRX with ticker symbol 196300 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date07 Dec 2016
- Listed onKRX: 196300
- Listed entityHLB Pep Co. Ltd.
- Exchange sectorHealth technology
- ISINKR7196300008
- Share price4,370.00 KRW (-4.48% on the day) · 2026-10-14
- Market capitalisation43,434,807,658.00 KRW
- EPS (diluted, trailing year)-342.59 KRW
- Volume (last session)12,109
Financials of Anygen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 4.96B KRW | -642.5M KRW | -5.01B KRW |
| 2024 | 6.23B KRW | -6.79B KRW | -2.95B KRW |
| 2023 | 5.61B KRW | -9.08B KRW | -3.85B KRW |
| 2022 | 8.66B KRW | -6.20B KRW | -1.38B KRW |
| 2021 | 10.27B KRW | -1.69B KRW | 2.35B KRW |
Detailed financial statements for Anygen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Anygen
4 dated milestones of Anygen across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Anygen is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by HLB.
Web traffic of Anygen
Websites that share an audience with Anygen (anygen.com).
Websites whose visitors overlap most with Anygen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
anyzenkorea.com | anyzenkorea.com | 100% | #5,970,879 | β | |
newsmac.co.kr | newsmac.co.kr | 79% | #1,822,082 | β |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Anygen
Complete news archive for Anygen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Anygen
Anygen was founded in 2000 and raised its 1st funding round 14 years after it was founded.
Anygen is headquartered in Gwangju, South Korea.
Jae Kim is the CEO of Anygen, as recorded in our data.
Anygen has 83 employees.
Annual revenue of Anygen is $3.43M as on Dec 31, 2025.
Founded in 2000 and based in Gwangju, South Korea, operations center on the biotech sector with GMP and non-GMP production of custom, generic, and catalog peptides. Services are delivered via the Nano-Bio Research center. Three drug candidates are under development in the GIST unit: an anti-cancer agent targeting head and neck cancers, a peptide-based treatment for neuropathic pain, and an oral delivery platform. Licensing is anticipated after preclinical trials.
Yes, Anygen is publicly traded on KRX under the ticker symbol 196300.
Anygen has 2 investors. Key investors include HLB, and Solidus Investment.
Yes. Anygen was acquired by HLB in March 2025.

